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Abstract

Cardiac imaging is under intense scrutiny as a contributor to health care costs, with multiple initiatives
under way to reduce and eliminate inappropriate testing. Appropriate use criteria are valuable guides to
selecting imaging studies, but until recently have focused on the test rather than the patient. Patientcentered means are needed in order to define the true value of imaging for patients in specific clinical
situations. This article provides a definition of high value cardiac imaging. A paradigm to judge the
efficacy of echocardiography in the absence of randomized controlled trials is presented. Candidate
clinical scenarios are proposed in which echocardiography constitutes high value imaging, as well as
stratagems to increase the likelihood that high value cardiac imaging takes place in those circumstances.
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Cardiac imaging has come under intense scrutiny as a contributor to rising health care costs in the
United States. Attention has been focused on the number of cardiac imaging studies performed,
including echocardiography. Volume is easy to measure; a far more difficult – and more important – task
is to ascertain the value of imaging for specific patients or groups of patients. The critical issue is not
how many studies are being done, but that they are done in circumstances where the results will
enhance the care of the patient – and not done when the results will not make a difference – so that
studies lead to better outcomes.
Increased demand for testing is due to both patient- and physician-related factors (1, 2). Among the
drivers are physician training which encourages a culture of completeness regardless of cost or of effect
on others; misaligned financial incentives; effective marketing of new technologies to physicians in the
absence of comparative effectiveness data with which physicians can assess the value of that
technology; and fear of malpractice suits, encouraging the practice of defensive medicine. On the
patient side, Americans are enamored of high technology and may perceive that more tests are by
definition equal to better care. Direct-to-consumer marketing influences patients’ preferences for
testing; and a health care system in which patients are insulated from the true fiscal costs of testing also
drives demand.
Recent data indicate that the rate at which cardiac imaging is performed not only is no longer increasing
but has begun to drop. While the General Accounting Office (GAO) reported in 2008 that Medicare
spending on imaging services under the Part B physician fee schedule more than doubled from 2000
through 2006, a subsequent MEDPAC Report to Congress noted that annual rate of growth in the
number of echocardiograms provided per Medicare beneficiary was only 2.6% between 2005 and 2009,
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and decreased by 0.8% per annum between 2009 and 2010. (3) On the cost side, payments to
cardiologists for noninvasive diagnostic imaging decreased a total of 33% between 2006 and 2010,
reversing the increases seen during the preceding six years. (4) Multiple explanations have been cited
for this phenomenon, which is sometimes referred to as “bending the cost curve.” They include the
promulgation of appropriate use criteria for cardiac imaging by professional societies such as the
American College of Cardiology Foundation (ACCF) and the American Society of Echocardiography (ASE),
among others. These documents evaluate the relative benefits and risks of an imaging study to
determine whether it is reasonable to consider performing the study for a specific indication. (5) The
terminology used to describe the three appropriateness categories has evolved for greater clarity since
their original publication. Studies for a specific indication were initially divided into Appropriate,
Uncertain or Inappropriate categories. The terminology has been revised to Appropriate Care, May be
Appropriate Care, and Rarely Appropriate Care, recognizing that a study which is rarely appropriate may
be precisely correct for a specific patient. (6) Stated another way, the goal for Rarely Appropriate studies
is not zero! Education programs such as the American Board of Internal Medicine’s “Choosing Wisely”
campaign have been directed at patient and providers. Commercial insurers have turned to radiology
benefits managers (RBM’s) in an attempt to reduce test ordering which they deem inappropriate, while
Medicare has adopted payment reductions to providers.
Reducing Overutilization
The interest in limiting inappropriate cardiac testing stems not just from containing costs. Excess testing
carries the potential for downstream ill effects. When a study which may have good specificity is
ordered on a population in whom a disorder has a low prevalence, the few “abnormal” results are more
likely to be false positives than true positives. This can cause anxiety on the part of the patient and leads
to unwarranted further testing which carries its own inherent risks. Conversely, a false negative result
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provides false reassurance and the potential for delayed diagnosis. These concepts are explicitly
recognized by the ACCF in its definition of an appropriate imaging study as “one in which the expected
incremental information, combined with clinical judgment, exceeds the expected negative
consequences by a sufficiently wide margin for a specific indication that the procedure is generally
considered acceptable care and a reasonable approach for the indication.” (5)
Appropriate use stratagems have been employed to examine and vet imaging studies once they have
been ordered, to determine whether they are being ordered for appropriate reasons. Methodologies
focusing on studies after they have been ordered are suited to reducing overutilization. Research in
community as well as academic settings has shown that from 9-20% of transthoracic and stress
echocardiograms are ordered for inappropriate indications. (7-11) A much smaller proportion of
requested transesophageal studies is rated as inappropriate. (12) The reasons for the disparity have not
been studied, but might include differences in specialties of the ordering physicians (i.e., cardiologists
versus non-cardiologists) for transesophageal studies compared with transthoracic or stress
echocardiography. The ease with which a transthoracic or stress echocardiogram can be ordered,
contrasted with the fact that transesophageal studies are semi-invasive and are directly performed by a
cardiologist who must actively assent to their performance, may play a role in differing rates of
appropriateness. Applying appropriate use criteria had previously been a manual undertaking,
consisting of matching the clinical scenario to a list of criteria on paper and uncovering the
appropriateness score. An application for myocardial perfusion imaging is available for both major
smartphone platforms, and one for echocardiography has been announced. The American College of
Cardiology has designed Imaging in FOCUS, a voluntary, web-based decision support program designed
to reduce inappropriateness in cardiac imaging. FOCUS demonstrated a reduction in inappropriate
SPECT myocardial perfusion imaging ordering among participants, from 11% of studies before using
FOCUS to 5% after. (13) ASE has co-developed a FOCUS module for transthoracic echocardiography. It is
5

reasonable to expect comparable improvements in the degree of study appropriateness when this tool
is applied to transthoracic echocardiography, but this hypothesis has yet to be tested beyond a pilot
study. (11). FOCUS is evolving into a robust, multi-modality program which links with commercially
available electronic health records and provides integrated decision support at the point of order entry.
(14)
Defining and identifying high value imaging
In the quest for high value imaging, rooting out cardiac imaging studies which are of questionable
appropriateness by looking at the study is one part of the solution. However, if examining
appropriateness begins once a test has been ordered, the process is entered at the midpoint of the
dimensions of care framework for evaluating the quality of cardiac imaging described by the ACCF
(Figure 1). This framework starts with the patient, recognizing that efforts at enhancing the value of
imaging studies must be patient-centric rather than test-centric. Focusing efforts at the patient level
uncovers not only which patients do not need an imaging study, but also identifies patients who should
have imaging studies to detect or risk stratify diseases. Such high value imaging may lead to
management changes which improve outcomes; or alternatively, lead to the imaging study which most
conclusively and efficiently excludes a disease, thereby reducing both patient anxiety and downstream
costs. This approach might better be conceptualized as “bending the value curve,” since the goal of
managing cardiac imaging is not just lower costs, but higher value to the patient and the health system.
The concept of developing an outcomes-based imaging cycle backed by evidence is not new (15) but
bears explication, particularly as the American health care system continues to transform.
Value in health care has been defined as health outcomes achieved per dollar spent. (16) Determining
what is high value cardiac imaging requires measurable outcomes which are specific to a given
condition. Outcomes, in the numerator, must be achieved efficiently; that is, the total cost of care for
6

the condition must be calculated, and not merely the cost of an individual service. A more expensive
test which reduces the overall cost of care may be a good investment of health care dollars. Diagnostic
studies do not by themselves cure, or change outcomes. Yet, high value imaging, by being performed in
the correct part of the care cycle, conceptually can reduce the overall cost of care if it leads to a better
health outcome. While the most critical outcomes for patients are increased survival, and recovery or
improved health, other metrics include time to recovery, avoiding treatment-related side effects,
avoidance of complications, sustained health and function, and avoiding care-induced illnesses.
The highest level of evidence for the value of an imaging study would come from a randomized,
controlled trial which measures specified outcomes. An example of such a study is the PROspective
Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) Trial, a randomized trial funded by
the National Heart, Lung and Blood Institute of the clinical effectiveness of diagnostic strategies in
patients with chest pain, who are randomized to either functional (exercise ECG, stress
echocardiography or stress nuclear) testing versus anatomic testing (coronary CT angiography). (17)
Randomized trials for an accepted technology which is already in clinical use – such as echocardiography
– as part of a diagnostic and treatment strategy are unlikely to be conducted, due to the large number
of conditions for which echocardiography is performed, and perhaps also due to lack of sponsor
enthusiasm for investing in what are perceived to be mature technologies.
An alternate, frequently cited paradigm to judge the value of imaging employs a six-tiered, hierarchical
model to conceptualize diagnostic imaging as part of a larger system whose goal is to treat patients
effectively and efficiently. Level 1 is technical efficacy, comprising variables needed to produce a high
quality image. Level 2 is diagnostic accuracy efficacy, such as percent of correct diagnoses, positive and
negative predictive value, sensitivity and specificity, as well as receiver operating curves. Level 3,
diagnostic thinking efficacy, describes the percentage of cases in which the image was helpful in making
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the diagnosis, the difference in the clinician’s estimation of post- versus pre-test probability and the like.
Level 4, therapeutic efficacy, consists of the percentage of times the image affects management or
changes the diagnostic or therapeutic plan. Level 5 describes patient outcome efficacy, being the
percentage of patients who improve after the test compared with those without it, morbidities avoided,
change in quality-adjusted life years (QALYs) based on the test, and similar metrics. Finally, level 6,
societal efficacy, comprises the benefits and costs of the imaging strategy from a societal viewpoint. (18)
(Table 1)
The value of cardiac imaging can be assessed if information about the higher levels of efficacy cited in
the model is available. For a given condition, an imaging study can lead to changes in diagnostic thinking,
such as uncovering the presence and severity of a disorder. Conversely, a test may confirm the absence
of a condition, such a decline in left ventricular systolic function during a course of cancer
chemotherapy, allowing treatment to continue as planned by the treating clinician. The test results bring
about an evidence-based change in management that has been proven in randomized, controlled trials
to improve patient outcomes. This approach might constitute an adequate surrogate for randomized,
controlled trials of the imaging modality itself (19, 20)
Aspects of the candidate imaging study itself also enter into the value equation. In all forms of testing, a
good candidate predictor should have a favorable risk-benefit ratio, reasonable cost, acceptability and
convenience, all of which are characteristic of echocardiography. (21) With respect to candidate
conditions, a “commonsense checklist” would consist of the following. One should apply the predictor
to diseases with major morbidity, for which some effective treatment is available which is not equally
effective for all persons. The candidate test should allow more accurate classification of individuals into
categories in which treatment is or is not indicated. The incremental prediction should be beyond what
can be achieved with information which is already available. There should be consensus about and
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standardization of established predictors, and the predictor should be unambiguously defined and
measured. (21)
Opportunities to achieve high value cardiac imaging
Examples of cardiac conditions with significant morbidity which fit these criteria abound. In each case,
echocardiography reclassifies persons non-invasively, painlessly and without the use of ionizing
radiation, based on standardized criteria such as those for chamber quantification, stress
echocardiography and valvular regurgitation which have been promulgated in a series of guidelines
published by ASE and ACCF. (22-24)
An example candidate condition is heart failure (HF), which affects an estimated 5.7 million people in
the United States. (25) Many Class I recommended therapies for heart failure with reduced left
ventricular ejection fraction are supported by Level of Evidence A; that is, they are recommended based
on multiple randomized, controlled trials or meta-analyses conducted in multiple populations. Therapies
including angiotensin converting enzyme inhibitors or angiotensin receptor blockers; beta blockers;
implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death;
and cardiac resynchronization have been shown to reduce symptoms, decrease hospitalizations and
increase survival, depending on stage and symptom class. Treatment of systolic heart failure is
predicated upon identifying the clinical predictor decreased systolic left ventricular function, usually via
two-dimensional echocardiography, which is described as “[t]he single most useful diagnostic test in the
evaluation of patients with HF.” (26)
Chronic mitral regurgitation serves as another example. This disorder is characterized by a long latent
period in which patients can remain asymptomatic even in the face of developing left ventricular
dilation and systolic dysfunction; yet even patients with preserved left ventricular ejection fraction may
be at increased risk of death. Mitral valve surgery performed in an asymptomatic individual whose
9

ejection fraction has fallen below 60% is likely to prevent further deterioration in left ventricular
function and improve longevity, although the level of evidence is less robust (Level B: limited
populations evaluated; data derived from a single randomized trial or nonrandomized studies). Once
the ejection fraction falls even lower, the risk of surgery increases and postoperative survival is less.
Thus there exists a golden moment for patients with chronic severe mitral regurgitation, wherein
identification of the severity of regurgitation and tracking left ventricular systolic function leads to
surgical therapy which improves outcomes, and conversely where outcomes are appreciably worse if
the golden moment is missed. (27)
Other conditions where opportunities exist to achieve high value cardiac imaging leading to effective,
evidence-based treatments are listed in Table 2. (26, 28-31)
Enhancing the likelihood that high value cardiac imaging is provided
The risk of missed opportunities might increase as health care in the United States reorganizes into
episodes of care for a specific patient, for a specified condition, over a defined period of time. Global
payment schemes in which providers assume financial risk can be perceived as carrying with them
financial incentives to underutilize services, including imaging. (32) It is thus incumbent on the
cardiology profession to define what constitutes high value cardiac imaging in each care bundle or
episode of care. Even under a fee-for-service system where there are no incentives to underutilize
services, underuse of necessary care is common. (33) Nearly 40% of Medicare beneficiaries with newly
diagnosed heart failure do not have an assessment of left ventricular function, a recommended
performance measure for these patients. (34) Recent studies applying the appropriate use criteria to
cardiac testing reveal evidence of missed opportunities to detect and correctly treat heart disease. A
retrospective study of appropriate use criteria for coronary revascularization of patients with stable
coronary artery disease revealed that only 69% of patients with an appropriate indication for
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revascularization actually underwent revascularization. (35) The 2011 appropriate use criteria for
echocardiography were applied to 931 consecutive inpatients referred for transthoracic
echocardiography in 5 community hospitals in Italy, who were compared with 259 patients who had
been discharged without having been referred for an echocardiogram. The investigators determined
that 14.7% of requested studies fell into the inappropriate category. However, among the patients
discharged without an echocardiographic examination, 16.2% failed to have a study performed despite
an appropriate indication, most commonly worsening signs or symptoms of heart failure. (10)
The universe of clinical conditions in which an echocardiogram may be indicated is large, and the task of
deciding at what point the study becomes a high value test is challenging even for physicians trained in
cardiology. Determining in the clinic or at the bedside when an echocardiogram meets “high value”
criteria may be even more difficult for non-cardiologists, such as internal medicine specialist or general
practice physicians, who order 71% of echocardiograms. (36) What tools are available to assist clinicians
in ordering appropriate imaging tests for a given patient, while refraining from ordering ones of low
value? Clinical decision support systems, defined as “any electronic system designed to aid directly in
clinical decision making, in which characteristics of individual patients are used to generate patientspecific assessments or recommendations that are then presented to clinicians for consideration” are
promising means by which to improve cardiac test ordering. (37) Four recent reviews found moderate
strength evidence that decision support systems, integrated into computerized point of entry or
electronic health record systems, can improve the appropriate ordering of clinical studies. Decision
support systems varied in the effectiveness with which they improved the quality of care, as judged by
health care process measures such as performing preventive services, diagnostic test ordering, and
prescription of therapies. Data are sparse for effects on patient or economic outcomes. Few of the
individual studies reviewed examined imaging. (38-41)

11

From the foregoing, a two-sided paradigm for achieving high value cardiac imaging emerges, as cardiac
imaging must be “right sized” in two directions. The issue of inappropriate overutilization has been
recognized, and tools to identify and address it are appearing. Those initiatives work towards the
important goal of reducing the number of imaging studies where the ratio of positive outcomes to
dollars spent is unfavorable. In a complimentary manner, research is needed into scenarios where
inappropriate underutilization takes place. Circumstances where a favorable ratio of health care value
achieved relative to cost indicates that a study is high value must not be missed. A systematic approach
for research into the latter would identify controlled trials of cardiac conditions where therapies which
improve patient outcomes require imaging studies to detect candidates for treatment. Then,
investigations would delineate methods which start with the patient at the point of care for his or her
symptoms or condition, and alert care providers (some of whom may not be familiar with the nuances
of appropriate cardiac testing) to order precisely the right test. An ideal system would provide real-time
feedback so as to educate as well as inform the physician. Research would later be needed to discover
whether beneficial changes take place in practice patterns, and more important in patient outcomes and
societal efficacy.
Progress in this direction is evident from a recent prospective study which evaluated an appropriate use
criteria decision support tool for physicians ordering imaging studies for coronary artery disease. The
studies included stress echocardiography, as well as myocardial perfusion scintigraphy and coronary CT
angiography. In addition to examining the effects on test appropriateness, the investigators studied the
effects of using the tool on intended changes in medical therapy. The tool was employed at the point of
ordering, took on average two minutes of physician time to use, and the immediate feedback to the
physician provided an educational component. Comparing the first two months and the last two months
of the trial, ordering of rarely appropriate studies decreased from 22% to 6%, the percentage of
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appropriate studies increased from 49% to 61%, and intended changes in medical therapy increased
from 11% to 32%. (42)
Multimodality, disease-specific appropriate use criteria for imaging are now beginning to appear with
the publication of the 2013 document for cardiovascular imaging in heart failure. (43) This appropriate
use document differs from prior publications not only because it is the first to encompass multiple
imaging modalities. The authors identified five key clinical entry points or scenarios for heart failuredirected imaging, “emphasizing that each indication represents the specific ‘point-of-order’ for an
imaging study.” Each scenario reviews the rationale for imaging, delineates the choice of imaging
modalities, references the heart failure guidelines, and categorizes the appropriateness of each
modality. For the scenario “newly suspected or potential heart failure,” appropriate use
recommendations drill down to selection of imaging based on symptoms and signs, for malignancy with
cardiotoxic therapy, familial or genetic cardiomyopathy, known adult congenital heart disease, and
acute myocardial infarction.
Envisioning a system for promoting high value cardiac testing
One can hypothesize the form which an ideal system to ensure high value cardiac imaging might take.
The process would use a decision support tool at the point of care or ordering. It would begin with a set
of signs and symptoms or a disease state. Logic built into the decision support algorithm could
automatically pull patient-specific descriptors which are already present in the database, such as the
physical examination, severity of symptoms, co-morbid conditions such as malignancy, prior relevant
imaging or laboratory values such as creatinine, for its impact on choosing a dye study, among others. By
referencing appropriate use criteria for multimodality imaging, the system could prompt the clinician to
consider ordering an appropriate study for each specific case where indicated. It might be designed to
look back to prior, similar testing and, by matching elements in the report (such as mild, moderate or
13

severe regurgitation) and patient descriptors (such as symptom severity), inform the clinician whether a
study meets guideline recommendations to repeat the study, or whether to refrain from doing so if
these criteria are not met.
A means to harmonize expert opinion from cardiology with guidelines for the same condition by experts
in other disciplines might further improve test utilization. Conceptually, at least, clinicians might be most
familiar with recommendations in their own specialty’s literature. An example is syncope, a condition
treated by emergency medicine specialists as well as cardiologists. Syncope is ranked in the
echocardiography appropriate use guidelines as appropriate for “clinical symptoms or signs consistent
with a cardiac diagnosis known to cause lightheadedness/presyncope/syncope.” (44) Recommendations
similar to these have been made in multidisciplinary guidelines for the investigation of syncope
authored by experts in emergency medicine. (45, 46) Using decision rules found in the emergency
medicine literature for patients presenting to emergency rooms with syncope may improve the
diagnostic and therapeutic efficacy of echocardiography. Applying a syncope diagnostic protocol to
patients presenting to a hospital in the United Kingdom increased the percentage of echocardiograms
performed. Importantly, the authors noted that 75% of echocardiograms in the study group were
performed for significant clinical findings such as aortic stenosis. Compared with historical controls, the
number of examinations needed to make a diagnosis decreased significantly, implying that the
percentage of low yield echocardiograms was reduced. (47)
Efforts to reduce low value imaging represent an important start in ensuring appropriate use of
resources. Short term benefits are relatively easy to quantitate, at least economically in terms of dollars
saved. We must at the same time recognize and address the thornier problem of missed opportunities
for high value imaging. As the United States moves to value-based purchasing, diagnoses will be bundled
into payment groups, and pressure will mount to reduce costs. Physicians must improve the way they
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order cardiac imaging, moving beyond cost to the concept of value. Inappropriate underutilization as
well as overutilization must be reduced. In the latter case, failure to perform the right test at the right
time can lead to an even more unfortunate circumstance for patients, described by hockey great Wayne
Gretzky as “you miss 100% of the shots you never take.”

Acknowledgement
The author thanks Michael S. Lauer, M.D. for his helpful suggestions.

15

References
1. Emanuel EJ, Fuchs VR. The perfect storm of overutilization. JAMA. 2008 Jun 18;299(23):2789-91.
2. Palfrey S. Daring to practice low-cost medicine in a high-tech era. N Engl J Med. 2011 Mar
17;364(11):e21.
3. Medicare Payment Advisory Commission. Medicare Payment Advisory Commission. 2012 report to
congress on Medicare payment policy. Washington, DC: Medicare Payment Advisory Commission;
March 2012.
4. Levin DC, Rao VJ, Parker L, Frangos AJ. The sharp reduction in Medicare payments for noninvasive
diagnostic imaging in recent years: Will they satisfy the federal policymakers? J Am Coll Radiol.
2012;9:643,-647.
5. Patel MR, Spertus JA, Brindis RG, Hendel RC, Douglas PS, Peterson ED, et al. ACCF proposed method
for evaluating the appropriateness of cardiovascular imaging. J Am Coll Cardiol. 2005 Oct 18;46(8):160613.
6. Hendel RC, Patel MR, Allen JM, Min JK, Shaw LJ, Wolk MJ, et al. Appropriate use of cardiovascular
technology: 2013 ACCF appropriate use criteria methodology update: A report of the American College
of Cardiology Foundation Appropriate Use Criteria Task Force. J Am Coll Cardiol. 2013 Mar
26;61(12):1305-17.
7. Ward RP, Krauss D, Mansour IN, Lemieux N, Gera N, Lang RM, et al. Comparison of the clinical
application of the American College of Cardiology Foundation/American Society of Echocardiography
appropriateness criteria for outpatient transthoracic echocardiography in academic and community
practice settings. Journal of the American Society of Echocardiography. 2009 Dec;22(12):1375-81.
8. Mansour IN, Lang RM, Aburuwaida WM, Bhave NM, Ward RP. Evaluation of the clinical application of
the ACCF/ASE appropriateness criteria for stress echocardiography. Journal of the American Society of
Echocardiography. 2010 Nov;23(11):1199-204.
9. Willens HJ, Hendel RC, Inhaber FR, Chakko SC, Postel C, Hasan T, et al. Appropriateness use criteria for
transthoracic echocardiography: Relationship with radiology benefit managers preauthorization
determination and comparison of the new (2010) criteria to the original (2007) criteria. Am Heart J. 2011
Oct;162(4):772-9.
10. Ballo P, Bandini F, Capecchi I, Chiodi L, Ferro G, Fortini A, et al. Application of 2011 American College
of Cardiology Foundation/American Society of Wchocardiography appropriateness use criteria in
hospitalized patients referred for transthoracic echocardiography in a community setting. Journal of the
American Society of Echocardiography. 2012 Jun;25(6):589-98.
11. Bhave NM, Mansour IN, Veronesi F, Razi RR, Lang RM, Ward RP. Use of a web-based application of
the American College of Cardiology Foundation/American Society of Echocardiography appropriateness
16

use criteria for transthoracic echocardiography: A pilot study. Journal of the American Society of
Echocardiography. 2011 Mar;24(3):271-6.
12. Aggarwal NR, Wuthiwaropas P, Karon BL, Miller FA, Pellikka PA, American College of Cardiology
Foundation. Application of the appropriateness criteria for echocardiography in an academic medical
center. Journal of the American Society of Echocardiography. 2010 Mar;23(3):267-74.
13. Allen JM. A national initiative to improve utilization of cardiac imaging: The FOCUS learning
community and performance improvement module. Circulation: Cardiovascular Quality and Outcomes.
2011 November 2011;4(6 Supplement).
14. Imaging in "FOCUS." [Internet].: American College of Cardiology; 2013; cited April 19, 2013].
Available from: http://www.cardiosource.org/Science-And-Quality/Quality-Programs/Imaging-inFOCUS.aspx.
15. Douglas PS. Improving imaging: Our professional imperative. J Am Coll Cardiol. 2006 Nov
21;48(10):2152-5.
16. Porter ME. What is value in health care?. N Engl J Med. 2010 Dec 23;363(26):2477-81.
17. PROspective multicenter imaging study for evaluation of chest pain (PROMISE) [Internet].: U.S.
National Institutes of Health; 2012 [updated August 2012; cited October 30, 2012]. Available from:
http://clinicaltrials.gov/ct2/show/NCT01174550.
18. Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Medical Decision Making. 1991 AprJun;11(2):88-94.
19. Guyatt GH, Tugwell PX, Feeny DH, Haynes RB, Drummond M. A framework for clinical evaluation of
diagnostic technologies. CMAJ Canadian Medical Association Journal. 1986 Mar 15;134(6):587-94.
20. Lord SJ, Irwig L, Simes RJ. When is measuring sensitivity and specificity sufficient to evaluate a
diagnostic test, and when do we need randomized trials?. Ann Intern Med. 2006 Jun 6;144(11):850-5.
21. Ioannidis JP, Tzoulaki I. What makes a good predictor?: The evidence applied to coronary artery
calcium score. JAMA. 2010 Apr 28;303(16):1646-7.
22. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for
chamber quantification: A report from the American Society of Echocardiography's Guidelines and
Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with
the European Association of Echocardiography, a branch of the European Society of Cardiology. Journal
of the American Society of Echocardiography. 2005 Dec;18(12):1440-63.
23. Pellikka PA, Nagueh SF, Elhendy AA, Kuehl CA, Sawada SG, American Society of Echocardiography.
American Society of Echocardiography recommendations for performance, interpretation, and
application of stress echocardiography. Journal of the American Society of Echocardiography. 2007
Sep;20(9):1021-41.

17

24. Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA, et al. Recommendations
for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler
echocardiography. Journal of the American Society of Echocardiography. 2003 Jul;16(7):777-802.
25. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke
statistics--2012 update: A report from the American Heart Association. Circulation. 2012 Jan
3;125(1):e2-e220.
26. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update
incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in
adults A report of the American College of Cardiology Foundation/American Heart Association Task
Force on Practice Guidelines developed in collaboration with the International Society for Heart and
Lung Transplantation. J Am Coll Cardiol. 2009 Apr 14;53(15):e1-e90.
27. Bonow RO. Carabello BA. Chatterjee K. de Leon AC Jr. Faxon DP. Freed MD. Gaasch WH. Lytle BW.
Nishimura RA. O'Gara PT. O'Rourke RA. Otto CM. Shah PM. Shanewise JS. American College of
Cardiology/American Heart Association Task Force on Practice Guidelines. 2008 focused update
incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart
disease: A report of the American College of Cardiology/American Heart Association Task Force on
Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients
with Valvular Heart Disease). endorsed by the Society of Cardiovascular Anesthesiologists, Society for
Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008
Sep 23;52(13):e1-142.
28. American College of Emergency Physician, Society for Cardiovascular Angiography and Interventions,
O'Gara PT, Kushner FG, Ascheim DD, Casey DE,Jr, et al. 2013 ACCF/AHA guideline for the management of
ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American
Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Jan 29;61(4):e78-140.
29. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA,3rd, Freedman RA, Gettes LS, et al. 2012
ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based
therapy of cardiac rhythm abnormalities: A report of the American College of Cardiology
Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm
Society. J Am Coll Cardiol. 2013 Jan 22;61(3):e6-75.
30. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for
the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary: A report of the
American College of Cardiology Foundation/American Heart Association Task Force on Practice
Guidelines. J Am Coll Cardiol. 2011 Dec 13;58(25):2703-38.
31. Baddour LM. Wilson WR. Bayer AS. Fowler VG Jr. Bolger AF. Levison ME. Ferrieri P. Gerber MA. Tani
LY. Gewitz MH. Tong DC. Steckelberg JM. Baltimore RS. Shulman ST. Burns JC. Falace DA. Newburger JW.
Pallasch TJ. Takahashi M. Taubert KA. Committee on Rheumatic Fever, Endocarditis, and Kawasaki
Disease. Council on Cardiovascular Disease in the Young. Councils on Clinical Cardiology, Stroke, and
Cardiovascular Surgery and Anesthesia. American Heart Association. Infectious Diseases Society of
America. Infective endocarditis: Diagnosis, antimicrobial therapy, and management of complications: A
statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and
18

Kawasaki disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical
Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed
by the Infectious Diseases Society of America. Circulation. 2005 Jun 14;111(23):e394-434.
32. Mechanic RE, Altman SH. Payment reform options: Episode payment is a good place to start. Health
Aff. 2009 Mar-Apr;28(2):w262-71.
33. Asch SM, Sloss EM, Hogan C, Brook RH, Kravitz RL. Measuring underuse of necessary care among
elderly Medicare beneficiaries using inpatient and outpatient claims. JAMA. 2000 Nov 8;284(18):232533.
34. Curtis LH, Greiner MA, Shea AM, Whellan DJ, Hammill BG, Schulman KA, et al. Assessment of left
ventricular function in older medicare beneficiaries with newly diagnosed heart failure.
Circulation.Cardiovascular Quality & Outcomes. 2011;4(1):85-91.
35. Ko DT, Guo H, Wijeysundera HC, Natarajan MK, Nagpal AD, Feindel CM, et al. Assessing the
association of appropriateness of coronary revascularization and clinical outcomes for patients with
stable coronary artery disease. J Am Coll Cardiol. 2012 Nov 6;60(19):1876-84.
36. Pearlman AS, Ryan T, Picard MH, Douglas PS. Evolving trends in the use of echocardiography: A study
of Medicare beneficiaries. J Am Coll Cardiol. 2007 Jun 12;49(23):2283-91.
37. Kawamoto K, Houlihan CA, Balas EA, Lobach DF. Improving clinical practice using clinical decision
support systems: A systematic review of trials to identify features critical to success. BMJ. 2005 Apr
2;330(7494):765.
38. Garg AX, Adhikari NK, McDonald H, Rosas-Arellano MP, Devereaux PJ, Beyene J, et al. Effects of
computerized clinical decision support systems on practitioner performance and patient outcomes: A
systematic review. JAMA. 2005 Mar 9;293(10):1223-38.
39. Roshanov PS, You JJ, Dhaliwal J, Koff D, Mackay JA, Weise-Kelly L, et al. Can computerized clinical
decision support systems improve practitioners' diagnostic test ordering behavior? A decision-makerresearcher partnership systematic review. Implementation Science. 2011;6:88.
40. Jaspers MW, Smeulers M, Vermeulen H, Peute LW. Effects of clinical decision-support systems on
practitioner performance and patient outcomes: A synthesis of high-quality systematic review findings.
Journal of the American Medical Informatics Association. 2011 May 1;18(3):327-34.
41. Bright TJ, Wong A, Dhurjati R, Bristow E, Bastian L, Coeytaux RR, et al. Effect of clinical decisionsupport systems: A systematic review. Ann Intern Med. 2012 Jul 3;157(1):29-43.
42. Lin FY, Dunning AM, Narula J, Shaw LJ, Gransar H, Berman DS, et al. Impact of an automated
multimodality point-of-order decision support tool on rates of appropriate testing and clinical decision
making for individuals with suspected coronary artery disease: A prospective multicenter study. J Am
Coll Cardiol 2013 Jul 23;62:308–16.

19

43. Patel MR, White RD, Abbara S, Bluemke DA, Herfkens RJ, Picard M, et al. 2013
ACCF/ACR/ASE/ASNC/SCCT/SCMR appropriate utilization of cardiovascular imaging in heart failure. A
joint report of the American College of Radiology Appropriateness Criteria Committee and the American
College of Cardiology Foundation Appropriate Use Criteria Task Force. Journal of the American College
of Cardiology. 2013 May 28;61(21):2207-31.
44. American College of Cardiology Foundation Appropriate Use Criteria Task,Force, American Society of
Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure
Society of America, Heart Rhythm Society, et al.
ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 appropriate use criteria for
echocardiography. A report of the American College of Cardiology Foundation Appropriate Use Criteria
Task Force, American Society of Echocardiography, American Heart Association, American Society of
Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular
Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed
Tomography, Society for Cardiovascular Magnetic Resonance, American College of Chest Physicians.
Journal of the American Society of Echocardiography. 2011 Mar;24(3):229-67.
45. Sheldon RS, Morillo CA, Krahn AD, O'Neill B, Thiruganasambandamoorthy V, Parkash R, et al.
Standardized approaches to the investigation of syncope: Canadian Cardiovascular Society position
paper. Can J Cardiol. 2011 Mar-Apr;27(2):246-53.
46. Task Force for the Diagnosis and Management of Syncope. European Society of Cardiology (ESC).
European Heart Rhythm Association (EHRA). Heart Failure Association (HFA). Heart Rhythm Society
(HRS). Moya A. Sutton R. Ammirati F. Blanc JJ. Brignole M. Dahm JB. Deharo JC. Gajek J. Gjesdal K. Krahn
A. Massin M. Pepi M. Pezawas T. Ruiz Granell R. Sarasin F. Ungar A. van Dijk JG. Walma EP. Wieling W.
Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J. 2009
Nov;30(21):2631-71.
47. Farwell DJ, Sulke AN. Does the use of a syncope diagnostic protocol improve the investigation and
management of syncope?. Heart. 2004 Jan;90(1):52-8.

20

Figure Legends

Figure 1. Dimensions of care framework for evaluating quality of cardiovascular imaging.
From Douglas, P.; Chen, J.; Gillam, L.; Hendel, R.; Jollis, J.; Iskandrian, A.E.; Krumholz, H.M.; Massoudi, F.;
Mohler, E. III; McNamara, R.L.; Patel, M.R.; Peterson, E.; Spertus, J. Achieving quality in cardiovascular
imaging: proceedings from the American College of Cardiology-Duke University Medical Center Think
Tank on Quality in Cardiovascular Imaging. J Am Coll Cardiol 2006;48:2141-2151. Reproduced with
permission of Elsevier, Inc.
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